Oncogenic and tumor-suppressive forces converge on a progenitor niche at the benign-to-malignant transition.
2/5 보강
OpenAlex 토픽 ·
Cancer Cells and Metastasis
Cancer Genomics and Diagnostics
Angiogenesis and VEGF in Cancer
The benign-to-malignant transition is a defining step in cancer progression.
APA
Jose Reyes, Isabella Del Priore, et al. (2026). Oncogenic and tumor-suppressive forces converge on a progenitor niche at the benign-to-malignant transition.. Cell. https://doi.org/10.1016/j.cell.2026.03.032
MLA
Jose Reyes, et al.. "Oncogenic and tumor-suppressive forces converge on a progenitor niche at the benign-to-malignant transition.." Cell, 2026.
PMID
41990751 ↗
Abstract 한글 요약
The benign-to-malignant transition is a defining step in cancer progression. To investigate when and how malignancy initiation occurs and tissue reorganization proceeds, we combine single-cell and spatial transcriptomic profiling in mouse models of pancreatic ductal adenocarcinoma (PDAC) that capture spontaneous p53 loss. Among Kras-mutant cells, we find that oncogenic and tumor-suppressive programs, including those controlled by p53, CDKN2A, and SMAD4, are co-activated in a discrete progenitor-like population, engaging senescence-like responses. Using a framework we developed for spatial analysis, we show that a niche centered on these cells undergoes stepwise remodeling during tumor progression, mirroring invasive PDAC. Transient KRAS inhibition depletes progenitor-like cells and dismantles their niche, delaying malignancy initiation. Conversely, p53 suppression enables progenitor cell expansion, epithelial-mesenchymal reprogramming, and immune-privileged niche formation. These findings position the progenitor-like state at the convergence of cancer-driving mutations, plasticity, and tissue remodeling, revealing a critical window for intercepting malignancy.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- The polyamine inhibitor SAM486A increases the efficacy of adagrasib in non-small cell lung cancer cells harboring KRAS mutation.
- Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study.
- Drugging the 'undruggable' KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer.
- Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer.